Objective To explore the efficacy and pharmacoeconomic value of Bevacizumab combined with GC chem-otherapy regimen(Cisplatin +Gemcitabine)in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 86 patients with advanced NSCLC treated from July 2020 to July 2022 were selected and divided into control group(n =43)and observation group(n =43)according to treatment plan.The control group was given GC chemotherapy,and the observation group was given Bevacizumab combined with GC chemotherapy.The efficacy,occurrence of toxic and side effects and blood biochemical indexes before and after treatment were compared between the two groups,and cost-effectiveness analy-sis was performed.Results The objective remission rate of 58.14%(25/43)and disease control rate of 93.02%(40/43)in the observation group were higher than those in the control group[32.56%(14/43)and 72.09%(31/43)](P<0.05).After 2 and 4 courses of treatment,the serum carcinoembryonic antigen,carbohydrate antigen 125,neuron specific enolase,vascular endothelial growth factor and basic fibroblast growth factor in observation group were lower than those in control group(P<0.05).There was no significant difference in the total incidence of toxic and side effects between the two groups(P>0.05).The total cost of observation group was higher than that of control group(P<0.05).The cost-effectiveness ratio(790.67)was lower than that of the control group(901.31),and sensitivity analysis showed that cost-effectiveness analysis was stable and reliable.Conclusion In the treatment of advanced NSCLC patients,Bevacizumab combined with GC chemo-therapy can downregulate the levels of tumor markers and vascular endothelial factors,and improve the efficacy,with obvious cost-effectiveness advantage.
维普
万方数据